WAVE Life Sciences Ltd.
WVE
$13.02
-$0.33-2.47%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -60.55% | 103.75% | -14.98% | -7.06% | -4.42% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -60.55% | 103.75% | -14.98% | -7.06% | -4.42% |
| Cost of Revenue | 14.46% | 17.10% | 21.77% | 25.95% | 22.82% |
| Gross Profit | -172.58% | 31.54% | -161.52% | -216.51% | -207.59% |
| SG&A Expenses | 27.63% | 24.79% | 23.59% | 21.34% | 15.07% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.02% | 19.21% | 22.28% | 24.64% | 20.63% |
| Operating Income | -95.09% | 10.59% | -71.47% | -74.24% | -62.37% |
| Income Before Tax | -110.68% | 14.43% | -75.12% | -80.18% | -66.71% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -110.68% | 14.43% | -76.74% | -82.16% | -68.67% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -110.68% | 14.43% | -76.74% | -82.16% | -68.67% |
| EBIT | -95.09% | 10.59% | -71.47% | -74.24% | -62.37% |
| EBITDA | -98.99% | 10.50% | -76.27% | -80.61% | -69.07% |
| EPS Basic | -54.78% | 33.84% | -51.76% | -57.17% | -42.17% |
| Normalized Basic EPS | -54.78% | 33.83% | -50.74% | -56.00% | -41.18% |
| EPS Diluted | -52.57% | 33.09% | -52.52% | -57.97% | -43.05% |
| Normalized Diluted EPS | -52.57% | 32.81% | -52.52% | -57.95% | -43.06% |
| Average Basic Shares Outstanding | 22.01% | 30.89% | 30.80% | 30.13% | 30.64% |
| Average Diluted Shares Outstanding | 19.67% | 33.05% | 32.81% | 32.25% | 32.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |